Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015;11(3):163-9.
doi: 10.2174/1573399811666150317130440.

Engineering biomimetic materials for islet transplantation

Affiliations
Review

Engineering biomimetic materials for islet transplantation

Ethan Y Yang et al. Curr Diabetes Rev. 2015.

Abstract

A closed-loop system that provides both the sensing of glucose and the appropriate dosage of insulin could dramatically improve treatment options for insulin-dependent diabetics. The intrahepatic implantation of allogeneic islets has the potential to provide this intimate control, by transplanting the very cells that have this inherent sensing and secretion capacity. Limiting islet transplantation, however, is the significant loss and dysfunction of islets following implantation, due to the poor engraftment environment and significant immunological attack. In this review, we outline approaches that seek to address these challenges via engineering biomimetic materials. These materials can serve to mimic natural processes that work toward improving engraftment, minimizing inflammation, and directing immunological responses. Biomimetic materials can serve to house cells, recapitulate native microenvironments, release therapeutic agents in a physiological manner, and/or present agents to direct cells towards desired responses. By integrating these approaches, superior platforms capable of improving long-term engraftment and acceptance of transplanted islets are on the horizon.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

CLS has stock options in Converge Biotech Inc. (Miami, FL).

Similar articles

Cited by

References

    1. Raff H. Medical Physiology: A Systems Approach. New York: McGraw Hill; 2001.
    1. Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and adolescents from 2001 to 2009. Jama. 2014;311(17):1778–86. - PMC - PubMed
    1. Andreoli TE. Cecil Essentials of Medicine. 6. W.B. Saunders Co; 2003.
    1. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, et al. Five-year follow-up after clinical islet transplantation: Strategic opportunities in clinical islet transplantation. Diabetes. 2005;54(7):2060–9. - PubMed
    1. Bruni A, Gala-Lopez B, Pepper AR, Abualhassan NS, Shapiro AJ. Islet cell transplantation for the treatment of type 1 diabetes: recent advances and future challenges. Diabetes, metabolic syndrome and obesity: targets and therapy. 2014;7:211–23. - PMC - PubMed

Publication types

Substances